Retatrutide and fatty liver — MASH resolution rates in Phase 2

PharmD_Rodriguez said:

The glucagon component looks paradoxical and is not.

This is exactly what I could not find anywhere else. I will report back once I have actually tried it.

Adding the clinical framing, because it changes how the question reads. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

Dr.EM_Chicago said:

The liver data is among the strongest non-weight findings in the class.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. Filing an objection on the n=1 problem. Personal experience is genuine evidence about one person and very weak evidence about anybody else, and this thread keeps promoting the first into the second.

Adding the numbers, since they settle part of this. Worth stating the units and the reference range whenever you post a number here. A large fraction of the apparent disagreement in these threads is two people using different units and both being right.

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Carry on.